These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11681238)

  • 1. [Adriamycin (doxorubicin)].
    Ogura M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1331-8. PubMed ID: 11681238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
    Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid infusion rituximab changing practice for patient care.
    Al Zahrani A; Ibrahim N; Al Eid A
    J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
    Hehn ST; Miller TP
    Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous venous infusion in cancer chemotherapy].
    Ota K
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):798-805. PubMed ID: 2580486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment strategies for aggressive lymphoma.
    Younes A
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
    Davidson KL; Devaney MB; Tighe JE; Rogers SY; Dunlop DJ; Mackie MJ; Thomas RV; Johnson PR;
    Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed.
    Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.